GSK agreed to acquire Nuvalent for approximately $10.6 billion, one of the largest biotech acquisitions of 2026. The transaction adds late-stage ROS1 and ALK targeted oncology assets and significantly accelerates GSK’s effort to rebuild…
Incyte agreed to acquire Vega Therapeutics for up to $2.0 billion, adding Phase 3 asset VGA039, a first-in-class Protein S-modulating antibody for von Willebrand disease. The deal represents Incyte’s most significant strategic move beyond…
Nurix and Roche announced a global collaboration for bexobrutideg, a potential best-in-class BTK degrader across hematology and immunology.
Eli Lilly signed a collaboration with Ascidian worth up to $1.9B to develop in vivo RNA exon-editing therapies for inherited kidney diseases, validating RNA exon editing as a major emerging genetic medicine modality.
YolTech Therapeutics raised $70M in a Series C financing to expand what is currently one of China’s most advanced in vivo CRISPR and base-editing platforms, with programs spanning sickle cell disease, beta-thalassemia, ATTR, familial…
Waypoint Bio emerged from stealth with a $20M Series A financing to advance multiple CAR-T investigator-initiated trials in China while developing an AI-enabled spatial pooled screening platform for next-generation target discovery.
Bristol Myers Squibb announced a strategic enterprise partnership with Anthropic to deploy Claude Enterprise across research, clinical development, manufacturing, regulatory, and commercial operations.
GSK has signed an oligonucleotide licensing agreement with China-based SiranBio worth up to $1 billion to develop SA030, a Phase 1-stage ALK7-targeting therapy for metabolic disease and abdominal fat reduction.
CellCentric has raised $220 million in a Series D financing to advance inobrodib, an oral p300/CBP inhibitor for multiple myeloma, supporting ongoing Phase 2 studies and planned Phase 3 development.
Protagonist Therapeutics has opted out of its 50:50 US profit-sharing agreement with Takeda for rusfertide, granting Takeda full US commercial rights in exchange for up to $475 million in near-term payments and substantial downstream…
